Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin aspart addition versus higher-dose insulin degludec/liraglutide after prior IDegLira treatment in type 2 diabetes
2013-002878-47Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Higher-dose insulin degludec/liraglutide + metformin with Insulin aspart + insulin degludec/liraglutide + metformin (2 arms). Primary endpoint: Change from baseline in HbA1c. Started Jan 2014; status: completed.
02
Drugs
insulin degludec + liraglutideinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-002878-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002878-47.